Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism.
about
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug actionDifferential clinical profile of candesartan compared to other angiotensin receptor blockersA Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3βEffects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertensionNifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results.An overview of candesartan in clinical practice.Differential pharmacology and benefit/risk of azilsartan compared to other sartansAngiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progressionInternational Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension.Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.Candesartan: widening indications for this angiotensin II receptor blocker?Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.The MCH(1) receptor, an anti-obesity target, is allosterically inhibited by 8-methylquinoline derivatives possessing subnanomolar binding and long residence times.On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targetsCost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region.Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation.Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.Novel role of mechanosensitive AT1B receptors in myogenic vasoconstriction.Angiotensin II, oxidative stress and stem cell therapy: a matter of delicacy.Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats.
P2860
Q24595639-851D4001-AE0D-4552-805A-88F654065C49Q24613321-B85B1CCA-1450-4B06-98AB-FCBFA3EA14AAQ28550557-F78F030B-F28F-4A45-A99C-D56E42E3FC89Q33710477-80ADFBA0-9B67-4355-B29A-EF90787CBC12Q34488929-4020FCD6-B5D6-458F-B8C3-ADC02DA184CFQ35453845-31E02A4C-D4CF-488F-89D1-B1BB428F62E1Q35808748-CAED8FBD-2E42-44CB-B14C-5736CB8CABF6Q35876800-E09CFA67-608F-494C-8B1B-27132A755D8CQ36241932-41B82131-E1D0-4531-98E0-7078898C8DEEQ36383863-05FF6A83-1F22-429F-9C8C-057AF414E57CQ36410269-8F21E1A5-4D80-4F7F-B649-A1A3BE5D9A52Q37534746-D2C2CE6E-7003-4D8F-8FBB-AD50025CA145Q38061467-AD1B4AE1-5BE0-4622-B39D-8A2DBFFEF8EFQ38265769-D2848A2F-C889-4290-B084-97783B0B1EEEQ38545579-7A3ED626-1EA7-4AFB-9F8D-20788348795AQ38710840-387E32B3-1730-43FF-81EE-2D72DDCA6DC0Q38834278-86933019-4ADC-4373-B0D0-E05CDB58A9D4Q39162849-CAECCFEA-03C8-4264-B9C2-E2C90C1928EBQ39397383-6635B3E0-1E9C-4C79-947B-B1F7B19B6D35Q41860286-E24E5CA9-B3F2-4E1C-B3C3-81B0D3998083Q42859674-12828915-873B-4C08-9A82-7A7BE909EF6AQ43297016-CD482950-2F0E-48D8-9DD4-704D3B6306C2Q44055125-8883AB99-CDFF-44D3-9053-ED9C1D901CA7Q44160051-F4992003-D73F-4412-83D3-5132A4E37A3FQ46781620-1B62A6DA-997D-43C3-B120-E0BC5E604380Q48189466-F5CDFDAB-D060-4543-B6D8-497D2F82B6B4Q48521760-58437329-ED79-46E5-96EC-FAF5558E3955
P2860
Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@en
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@nl
type
label
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@en
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@nl
prefLabel
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@en
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@nl
P1476
Sartan-AT1 receptor interactio ...... ntagonism and inverse agonism.
@en
P2093
G Vauquelin
I Van Liefde
P304
P356
10.1016/J.MCE.2008.06.006
P577
2008-06-21T00:00:00Z